Switch to: Citations

Add references

You must login to add references.
  1. Data-Centric Biology: A Philosophical Study.Sabina Leonelli - 2016 - London: University of Chicago Press.
    Download  
     
    Export citation  
     
    Bookmark   103 citations  
  • Open Science, Philosophy and Peer Review.Michael A. Peters - 2014 - Educational Philosophy and Theory 46 (3):215-219.
    Download  
     
    Export citation  
     
    Bookmark   9 citations  
  • Why the Current Insistence on Open Access to Scientific Data? Big Data, Knowledge Production, and the Political Economy of Contemporary Biology.Sabina Leonelli - 2013 - Bulletin of Science, Technology and Society 33 (1-2):6-11.
    The collection and dissemination of data on human and nonhuman organisms has become a central feature of 21st-century biology and has been endorsed by funding agencies in the United States and Europe as crucial to translating biological research into therapeutic and agricultural innovation. Large molecular data sets, often referred to as “big data,” are increasingly incorporated into digital databases, many of which are freely accessible online. These data have come to be seen as resources that play a key role in (...)
    Download  
     
    Export citation  
     
    Bookmark   12 citations  
  • Open Access Digital Data Sharing: Principles, Policies and Practices☆.Natasha Susan Mauthner & Odette Parry - 2013 - Social Epistemology 27 (1):47 - 67.
    (2013). Open Access Digital Data Sharing: Principles, Policies and Practices☆. Social Epistemology: Vol. 27, No. 1, pp. 47-67. doi: 10.1080/02691728.2012.760663.
    Download  
     
    Export citation  
     
    Bookmark   6 citations  
  • The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development.Catherine M. Montgomery & Javier Lezaun - 2015 - Science, Technology, and Human Values 40 (1):3-29.
    In the last decade, the organization of pharmaceutical research on neglected tropical diseases has undergone transformative change. In a context of perceived “market failure,” the development of new medicines is increasingly handled by public-private partnerships. This shift toward hybrid organizational models depends on a particular form of exchange: the sharing of proprietary assets in general and of intellectual property rights in particular. This article explores the paradoxical role of private property in this new configuration of global health research and development. (...)
    Download  
     
    Export citation  
     
    Bookmark   12 citations